Diabetes complications and comorbidities

The dual Ang-2 and VEGF-A pathway inhibitor faricimab is noninferior to aflibercept for improving visual acuity in people with diabetic macular edema, and an individualized dosing strategy could help reduce treatment burden, suggest findings from the YOSEMITE and RHINE trials.

Zhou JB et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0497-y

Cavan D et al. Diabetes Res Clin Prac 2018; 143: 170–178. doi: 10.1016/j.diabres.2018.07.004

van Stee MF, de Graaf AA, Groen AK. Cardiovasc Diabetol 2018; 17: 94. doi: 10.1186/s12933-018-0738-4

Liu G, Xu D, Wang F. Diabetes Res Clin Prac 2018; 142: 243–253. doi: 10.1016/j.diabres.2018.05.043

The CLEOPATRA trial results show that wearing a mask that emits blue–green light during sleep does not reduce the progression of non-central diabetic macular edema.

In this editorial, Rishi Singh and colleagues provide their perspective on the future of proliferative diabetic retinopathy treatment following the completion of the CLARITY and Protocol S studies.

Here we provide an overview of the seven Cochrane reviews published in June that covered topics relating to diabetes, including glycemic control for prevention of renal failure, phototherapy for foot ulcers, and anti-vascular endothelial growth factor treatment for diabetic macular edema.

Eye 2017; 31: S1–S20. doi: 10.1038/eye.2017.53

Results of the CLARITY trial suggest that aflibercept treatment may produce better visual outcomes than laser photocoagulation in patients with proliferative diabetic retinopathy.

Eye 2017; 31: 1358–1364. doi: 10.1038/eye.2017.69

Bahrami B et al. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1133–1140. doi: 10.1007/s00417-017-3624-y

Shah SU, Maturi RK. Drugs 2017; 77: 481–492. doi: 10.1007/s40265-017-0704-6

Knickelbein JE, Abbott AB, Chew EY. Curr Diab Rep 2016; 16: 90. doi: 10.1007/s11892-016-0786-7

Lee R et al. Eye and Vis 2015; 2: 17. doi: 10.1186/s40662-015-0026-2